Sun Pharma Advanced Research Co (NSE:SPARC) Cyclically Adjusted PB Ratio: (As of Aug. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SPARC Sun Pharma Advanced Research Co Ltd NSE:SPARC
47 GF Score
Price ₹197.36
GF Value ₹4,409.68
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Sun Pharma Advanced Research Co Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sun Pharma Advanced Research Co  (NSE:SPARC) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Sun Pharma Advanced Research Co Cyclically Adjusted PB Ratio Related Terms


Sun Pharma Advanced Research Co Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Sun Pharma Advanced Research Co's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sun Pharma Advanced Research Co Cyclically Adjusted PB Ratio Chart

Sun Pharma Advanced Research Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 54.36 31.65 64.47 29.31 17.70

Sun Pharma Advanced Research Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 29.67 0.00 17.70 0.00

NSE:SPARC vs ZTS: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharma Advanced Research Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sun Pharma Advanced Research Co Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sun Pharma Advanced Research Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Sun Pharma Advanced Research Co's Cyclically Adjusted PB Ratio falls into.


NSE:SPARC
47GF Score
Sun Pharma Advanced Research Co Ltd NSE:SPARC
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sun Pharma Advanced Research Co Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Sun Pharma Advanced Research Co's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Sun Pharma Advanced Research Co's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/167.3573*167.3573
=0.000

Current CPI (Jun. 2026) = 167.3573.

Sun Pharma Advanced Research Co Quarterly Data

Book Value per Share CPI Adj_Book
201609 10.460 105.961 16.521
201612 0.000 105.196 0.000
201703 6.406 105.196 10.191
201706 0.000 107.109 0.000
201709 5.731 109.021 8.798
201712 0.000 109.404 0.000
201803 7.361 109.786 11.221
201806 0.000 111.317 0.000
201809 8.715 115.142 12.667
201812 0.000 115.142 0.000
201903 11.305 118.202 16.006
201906 0.000 120.880 0.000
201909 5.316 123.175 7.223
201912 0.000 126.235 0.000
202003 -0.711 124.705 -0.954
202006 0.000 127.000 0.000
202009 -1.784 130.118 -2.295
202012 0.000 130.889 0.000
202103 -6.421 131.771 -8.155
202106 0.000 134.084 0.000
202109 0.179 135.847 0.221
202112 0.000 138.161 0.000
202203 1.149 138.822 1.385
202206 0.000 142.347 0.000
202209 -4.310 144.661 -4.986
202212 0.000 145.763 0.000
202303 15.801 146.865 18.006
202306 0.000 150.280 0.000
202309 10.221 151.492 11.291
202312 0.000 152.924 0.000
202403 3.875 153.035 4.238
202406 0.000 155.789 0.000
202409 0.000 157.882 0.000
202412 0.000 158.323 0.000
202503 -6.685 157.552 -7.101
202506 0.000 159.755 0.000
202509 -10.620 162.289 -10.952
202512 0.000 163.281 0.000
202603 41.255 164.272 42.030
202606 0.000 167.357 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Sun Pharma Advanced Research Co (NSE:SPARC) Overvalued in 2026?

Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be undervalued. The current stock price of ₹197.36 is trading 95.5% below its estimated GF Value™ of ₹4,409.68. GuruFocus considers Sun Pharma Advanced Research Co to be Possible Value Trap.

Key valuation signals for NSE:SPARC:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ₹4,409.68 vs. price of ₹197.36 (95.5% below fair value)
  • GF Score™: 47/100 with 4 warning signs

No single metric tells the full story. See the NSE:SPARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sun Pharma Advanced Research Co Business Description

Other Exchanges 532872:India
Address Off Mahakali Caves Road, 17-B, Mahal Industrial Estate, Andheri (East), Mumbai, MH, IND, 400093
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
47GF Score

Get the complete analysis for NSE:SPARC

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹197.36
Price
₹4,409.68
GF Value